News Results for Summit Therapeutics (SUMM)

  • 24 Jan
    13:57
    Summit Therapeutics operations head David Roblin resigns

    Summit Therapeutics said chief operating officer David Roblin had resigned, effective at the end of January. He would also relinquish the role of chief medical officer and president of R&D....

  • 15 Jan
    12:45
    Director Deals - Summit Therapeutics PLC (SUMM)

    Robert Duggan, Non Executive Director, sold 33,321,870 shares in the company on the 14th January 2020 at a price of 22.10p. The Director now holds 211,123,385 shares. Story provided by...

  • 16 Oct
    13:11
    Summit Therapeutics CEO Glyn Edwards to present at San Francisco conference

    Summit Therapeutics said chief executive Glyn Edwards would present at an industry conference in San Francisco. Edwards would present at the 2019 BIO Investor Forum on 22 October. At 1:11pm:...

  • 11 Oct
    13:52
    Summit Therapeutics losses deepen on higher R&D spend

    Pharmaceutical company Summit Therapeutics posted a deeper second-quarter loss amid a rise in R&D spending. Pre-tax losses for the three months through September amounted to $7.6m, compared to...

  • 17 Jul
    13:08
    Summit Therapeutics highlights potential of gonorrhoea treatment at key conference

    Summit Therapeutics said that it had highlighted the potential of its pre-clinical new class antibiotic to treat all gonorrhoea, including multi-drug resistant strains, at the STI & HIV World...

  • 12 Jun
    13:09
    Summit Therapeutics books first-quarter loss on higher R&D spend

    Antibiotics developer Summit Therapeutics booked a first-quarter loss as it ramped up R&D spending. Pre-tax losses for the three months through March amounted to $6.3m, compared to losses of...

  • 15 Apr
    08:06
    Summit Therapeutics presents antibiotic concept data at Amsterdman conference

    Summit Therapeutics said it had presented proof of concept data for a series of new antibiotics at a conference in Amsterdam. The data was presented for a DDS-04 series of new mechanism...

  • 27 Mar
    13:22
    Summit Therapeutics swings to profit

    Summit Therapeutics swung to an annual profit as it continued to develop its antibiotic portfolio. Pre-tax profit for the year through amounted to £5.0m, compared to a loss of £24.0m on-year....

  • 13 Feb
    13:10
    Summit Therapeutics doses first patient in antibiotic trial

    Summit Therapeutics said it had dosed the first patient in the third phase of a clinical trial of an antibiotic to treat C.difficile infection. The treatment, ridinilazole, had achieved...

  • 08 Jan
    08:09
    Summit Therapeutics says shares from $25m raising to be admitted imminently

    Summit Therapeutics said the admission of new shares in the company connected with its proposed $25m capital raising was expected to occur on or around this Wednesday. The admission to AIM was for...

  • 17 Dec
    07:21
    Summit Therapeutics to raise $25m; CFO to stand down

    Antibiotic developer Summit Therapeutics launched a share issue to raise $25m, while also announce its chief financial officer Erik Ostrowski would leave at the end of December to pursue another...

  • 11 Dec
    13:43
    Summit Therapeutics losses deepen as expenses rise

    Summit Therapeutics posted a deeper third-quarter loss underpinned by higher R&D spending and expenses related to payments to executives. Pre-tax losses for the three months through September...

  • 24 Oct
    16:45
    Director Deals - Summit Therapeutics PLC (SUMM)

    David Wurzer, Non Executive Director, exercised 19,444 shares in the company on the 24th October 2018 at a price of 1.00p. The Director now holds 46,123 shares. Story provided by...

  • 24 Oct
    16:40
    Director Deals - Summit Therapeutics PLC (SUMM)

    Dr Frank Armstrong, Chairman, exercised 41,666 shares in the company on the 24th October 2018 at a price of 1.00p. The Director now holds 122,204 shares. Story provided by StockMarketWire.com...

  • 24 Oct
    16:40
    Director Deals - Summit Therapeutics PLC (SUMM)

    Leopoldo Zambeletti, Non Executive Director, exercised 19,444 shares in the company on the 24th October 2018 at a price of 1.00p. The Director now holds 27,337 shares. Story provided by...

  • 24 Oct
    16:40
    Director Deals - Summit Therapeutics PLC (SUMM)

    Leopoldo Zambeletti, Non Executive Director, sold post-exercise 11,358 shares in the company on the 24th October 2018 at a price of 28.10p. The Director now holds 15,979 shares. Story provided by...

  • 24 Oct
    16:40
    Director Deals - Summit Therapeutics PLC (SUMM)

    Valerie Andrews, Non Executive Director, exercised 19,444 shares in the company on the 24th October 2018 at a price of 1.00p. The Director now holds 49,123 shares. Story provided by...

  • 03 Oct
    13:15
    Summit Therapeutics displays antibiotic details at San Francisco gathering

    Antibiotic developer Summit Therapeutics said it was highlighting a potential treatment for bacterial infections at a key industry conference in San Francisco. Ridinilazole could be used as a...

  • 05 Sep
    13:26
    Summit Therapeutics selects lead gonorrhoea treatment candidate

    Summit Therapeutics said it had nominated a lead clinical candidate from its first gonorrhoea treatment series. In in vitro studies of the candidate, SMT-571, killed N. gonorrhoeae through a novel...

  • 29 Aug
    13:17
    Summit Therapeutics CEO to outline antibiotic plans in New York

    Summit Therapeutics said chief executive Glyn Edwards would next month present on the company's plans to advance its new mechanism antibiotic at a conference in New York. The presentation would be...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Dr Frank Armstrong, Chairman, exercised 41,096 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 80,538 shares. Story provided by StockMarketWire.com...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    David Wurzer, Non Executive Director, exercised 19,179 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 26,679 shares. Story provided by...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Stephen Davies, Director, exercised 19,179 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 621,660 shares. Story provided by StockMarketWire.com Director...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Valerie Andrews, Non Executive Director, exercised 19,179 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 29,679 shares. Story provided by...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Barry Price, Non Executive Director, exercised 19,179 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 126,390 shares. Story provided by...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Barry Price, Non Executive Director, sold post-exercise 9,851 shares in the company on the 18th July 2018 at a price of 36.50p. The Director now holds 116,539 shares. NOTE: Sold to meet tax...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Leopoldo Zambeletti, Non Executive Director, exercised 19,179 shares in the company on the 18th July 2018 at a price of 1.00p. The Director now holds 19,179 shares. Story provided by...

  • 19 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Leopoldo Zambeletti, Non Executive Director, sold post-exercise 11,286 shares in the company on the 18th July 2018 at a price of 36.50p. The Director now holds 7,893 shares. NOTE: Sold to meet tax...

  • 17 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Dr Frank Armstrong, Chairman, bought 25,000 shares in the company on the 16th July 2018 at a price of 39.50p. The Director now holds 39,442 shares. Story provided by StockMarketWire.com Director...

  • 16 Jul
    09:00
    Director Deals - Summit Therapeutics PLC (SUMM)

    Glyn Edwards, Chief Executive Officer, bought 150,000 shares in the company on the 13th July 2018 at a price of 38.00p. The Director now holds 383,333 shares. Story provided by...

  • 10 Jul
    13:27
    Summit Therapeutics wins $4.5m grant for drug-resistant gonorrhoea treatment

    Summit Therapeutics said it won an up to $4.5m grant to support its work developing new treatments for drug-resistant gonorrhoea. The grant was offered by the CARB-X public-private partnership, a...

  • 27 Jun
    13:13
    Summit Therapeutics ends development of muscular dystrophy treatment

    Summit Therapeutics said it was discontinuing its development of ezutromid after the treatment failed to reach its objectives in a trail involving patients with Duchenne muscular dystrophy. The...

  • 11 Jun
    09:21
    Summit Therapeutics discovers new treatment option for gonorrhoea

    Summit Therapeutics said it had discovered a potential new treatment for gonorrhoeae. The second novel target was distinct from that of existing antibiotics and also from Summit's...

  • 05 Jun
    13:31
    Summit Therapeutics losses deepen on higher R&D spend

    Rare and infectious disease specialist Summit Therapeutics said its first-quarter losses deepened after it upped R&D spending. Pre-tax losses amounted to £6.8m, compared to a loss in the...

  • 23 Apr
    17:25
    Director Deals - Summit Therapeutics PLC (SUMM)

    Prof Stephen Davies, Non Executive Director, exercised 17,500 shares in the company on the 23rd April 2018 at a price of 1.00p. The Director now holds 602,481 shares. Story provided by...

  • 23 Apr
    17:20
    Director Deals - Summit Therapeutics PLC (SUMM)

    Barry Price, Non Executive Director, exercised 31,481 shares in the company on the 23rd April 2018 at a price of 1.00p. The Director now holds 107,211 shares. Story provided by...

  • 23 Apr
    13:21
    Summit Therapeutics advances gonorrhoea treatment plans

    Summit Therapeutics said it had advanced its studies of new antibiotic candidates for the treatment of gonorrhoea. The company updated its progress at the European Congress of Clinical...

  • 27 Mar
    07:37
    Summit Therapeutics launches £15.0m placement to fund treatment trials

    Summit Therapeutics launched a share placement to raise up to £15.0m to accelerate clinical trials of its treatments. New shares in the company would be issued at 180p each, representing a 5.3%...

  • 13 Mar
    13:45
    Summit Therapeutics discovers new compounds that kill gonorrhoea

    Summit Therapeutics said it had discovered a series of antibiotic compounds that kill gonorrhoea bacteria via new mechanisms of action. In early testing, the compounds were shown to have high...

  • 27 Dec
    08:44
    Summit in £10m antibiotics R&D deal

    Summit Therapeutics is to pay £10m in cash and shares for Discuva whose principal asset is a genetics-based technology platform for the generation of antibiotics. The company believes the deal...

  • 21 Dec
    09:20
    Summit enters licence agreement in Latin America

    Summit Therapeutics, a drug discovery and development company, has entered into an exclusive licence and commercialisation agreement granting Eurofarma Laboratorios rights in Latin America to...

  • 04 Dec
    13:33
    Summit schedules interim results announcement

    Summit Therapeutics has confirmed that the Company intends to announce its third quarter and nine months results to 31 October on 6 December. At 1:33pm: (LON:SUMM) Summit Therapeutics PLC share...

  • 22 Nov
    13:33
    Summit to participate in US investor conferences

    Summit Therapeutics has confirmed that it will participating in two upcoming investor conferences in New York City. These include: - 29th Annual Piper Jaffray Healthcare Conference - November 28,...

  • 20 Nov
    13:14
    Summit completes initial PhaseOut DMD trial

    Summit Therapeutics said it has completed the initial 24-weeks of dosing of ezutromid in patients with DMD in its Phase 2 clinical trial called PhaseOut DMD. The Company added that it continues to...

  • 09 Nov
    13:42
    Summit to present at Duchenne Conference

    Summit Therapeutics has confirmed that new preclinical data shows a positive effect of utrophin modulation on improving muscle health in DMD. The Company also announced that it and collaborators...

  • 06 Nov
    13:41
    Summit inks revenue sharing agreement with Wellcome Trust

    Summit Therapeutics confirmed that the Company has entered into an equity and revenue sharing agreement with the Wellcome Trust, covering potential future revenues generated by ridinilazole. "The...

  • 09 Oct
    13:11
    Summit highlights Microbiome Preservation during Ridinilazole treatment

    Summit has announced that at ID Week 2017, it presented further positive gut microbiome data of ridinilazole from its exploratory Phase 2 clinical trial. As was previously reported, the Company's...

  • 04 Oct
    13:03
    Summit to present at conference in Saint-Malo

    Summit Therapeutics has confirmed that the Company and its collaborators will be presenting at the 22nd International Congress of the World Muscle Society, which is taking place in Saint-Malo,...

  • 02 Oct
    13:29
    Summit to host R&D day

    Summit Therapeutics has confirmed that the Company will host an R&D Day featuring presentations from experts in quantitative muscle image analysis and CDI alongside Summit's management on 11...

  • 25 Sep
    13:46
    Summit joins cTAP

    Summit Therapeutics confirmed that the Company has joined the Collaborative Trajectory Analysis Project ('cTAP') to support cTAP's mission of accelerating the development of drugs to treat DMD...

  • 11 Sep
    13:34
    Summit awarded Barda contract worth up to $62m

    Summit Therapeutics has announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company a contract worth up to $62m. It said the funds will support the...

  • 05 Sep
    15:01
    Summit announces positive ridinilazole trial results

    Summit Therapeutics has announced positive top-line data from an exploratory Phase 2 clinical trial that support ridinilazole as a highly selective and potent antibiotic product candidate for the...

  • 14 Jun
    13:28
    Summit losses fall

    Summit Therapeutics has reported a loss for the three months ended 30 April 2017 of £4.8m, compared to a loss of £5.4m for the same period last year. The Company also confirmed a $22m milestone...

  • 13 Jun
    14:59
    Summit confirms date of Q1 results announcement

    Summit Therapeutics said it will announce its financial results for the first quarter ended 30 April on 14 June. At 2:59pm: (LON:SUMM) Summit Therapeutics PLC share price was -5p at 172.5p...

  • 05 Jun
    13:18
    Summit highlights benefits of ridinilazole at ASM Microbe

    Summit Therapeutics has announced that the Company presented new preclinical data on ridinilazole were at ASM Microbe 2017, which was held in New Orleans, US from 1-5 June 2017. "These positive...

  • 15 May
    13:06
    Summit completes PhaseOut DMD enrolment

    Summit Therapeutics confirmed the the Company has completed enrolment in PhaseOut DMD, a Phase 2 proof of concept clinical trial of the utrophin modulator, ezutromid, in patients with DMD....

  • 30 Mar
    14:18
    Summit changes registered office

    Summit Therapeutics has announced that the Company's registered office has changed to 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK with immediate effect. At 2:18pm:...

  • 27 Mar
    14:06
    Summit schedules FY results

    Summit Therapeutics will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2017 on Wednesday, 29 March 2017. At 2:06pm: (LON:SUMM) Summit Therapeutics...

  • 27 Mar
    13:53
    Summit to extend PhaseOut DMD clinical trial

    Summit Therapeutics has confirmed that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid, subject to regulatory...

  • 02 Feb
    14:10
    Summit to take part in investor conferences

    Summit Therapeutics has announced that company management will participate in three upcoming investor conferences taking place in New York City in February. - Canaccord Genuity Rare Disease and...

  • 01 Feb
    13:36
    Summit outlines Phase 3 programme for ridinilazole

    Summit Therapeutics has outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration ('FDA') and European...

  • 04 Oct
    16:48
    FTSE closes close to its record high

    The FTSE 100 continued to rally closer to its record high from last April. The blue chip index rose 2% to 7,120 as the pound hit a 31-year low against the dollar. The FTSE 250 broke to a new...

  • 08 Sep
    12:23
    Summit Therapeutics widens H1 loss

    Summit Therapeutics has posted an H1 loss of $17.9m, from a loss of $13.5m a year ago. Most of the losses were due to research and development expenses, followed by those for general and...

  • 10 May
    12:30
    Summit's FY net losses widen

    Summit Therapeutics has posted a net loss for the 12 months to 31 Jan 2016 of GBP17.1m, compared to a net loss of GBP11.3m for the previous 12 months. Cash and cash equivalents at 31 Jan were...

  • 28 Apr
    12:21
    Summit granted further US patent for ridinilazole

    Summit Therapeutics (SUMM) has announced the strengthening of its intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States...

  • 26 Apr
    12:21
    Summit's IND cleared by FDA

    Summit Therapeutics has announced that the US Food and Drug Administration has cleared the Company's investigational new drug (IND) application to expand the Phase 2 proof of concept clinical trial...

  • 11 Apr
    12:11
    Summit sets out findings from P2 CoDIFy trial

    Summit Therapeutics has announced the presentation today of major findings from the Phase 2 CoDIFy trial highlighting the potential of ridinilazole in the treatment of CDI at the 26th European...

  • 06 Apr
    12:04
    Summit CEO to present at healthcare conference

    Summit Therapeutics has announced that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company's 15th Annual Healthcare Conference, 13 April 2016 in New York City. At...

  • 30 Mar
    12:10
    Summit confirms positive P1 trial data for SMT C1100

    Summit Therapeutics says it has received positive interim data from a Phase 1 clinical trial evaluating a new oral formulation of its lead utrophin modulator, SMT C1100, for DMD. In this dose...

  • 29 Mar
    14:35
    Summit to present additional data at conference

    Summit Therapeutics will present additional data from the phase 2 CoDIFy trial at the 26th European Congress of Clinical Microbiology and Infectious Diseases. In the accompanying abstract...

  • 29 Feb
    12:50
    Summit supports Rare Disease Day

    Summit Therapeutics has announced its support for the ninth annual Rare Disease Day on 29 February 2016. The Rare Disease Day 2016 theme, Patient Voice, recognises the crucial role that patients...

  • 24 Feb
    12:14
    Summit publishes preclinical data

    Summit Therapeutics has announced the online publication of preclinical data in the Journal of Antimicrobial Chemotherapy supporting ridinilazole as a novel and potent antibiotic against CDI. The...

  • 17 Feb
    12:07
    Summit Therapeutics to participate at NY Orphan Drug Day

    Summit Therapeutics has announced that management will participate in one on one meetings at SunTrust Robinson Humphrey's 2016 Orphan Drug Day, taking place 23 February 2016 in New York City....

  • 03 Feb
    12:50
    Summit CEO to present at conference in New York

    Summit Therapeutics has confirmed that Mr Glyn Edwards, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference, 9 February 2016 in New York City. At 12:50pm:...

  • 21 Jan
    12:09
    Summit gets UK approval for drug trial

    Summit Therapeutics has announced that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2...

  • 20 Jan
    13:55
    Summit Therapeutics to present at the at the techinvest focussed Innovators & Investors Forum 2016

    Richard Pye, Director of Corporate Communications of Summit Therapeutics (SUMM) [SUMM] the drug discovery and development company, is to present at the Innovators & Investors Forum 2016 in...

  • 19 Jan
    12:05
    Summit granted European patent

    Summit Therapeutics has announced that the European Patent Office has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent...

  • 17 Dec
    12:18
    Summit losses widen

    Summit Therapeutics has reported a Q3 loss of £12.1m, compared to a loss of £8.4m for the nine months ended 31 October 2014. The Company had Cash and cash equivalents at 31 October 2015 of...

  • 14 Dec
    12:06
    Summit schedules Q3 results

    Summit Therapeutics has confirmed that it will be reporting its third quarter financial results for the period ending 31 October 2015 on Thursday, 17 December 2015. At 12:06pm: (LON:SUMM)...

  • 10 Dec
    12:07
    Summit to participate in the JMP Securities DMD Forum

    Summit Therapeutics has announced that it will be participating in the JMP Securities DMD Forum on Monday, 14 December 2015, in New York City. It stated that the day will focus on the key themes...

  • 03 Dec
    12:16
    Summit's CFO to present at Oppenheimer Healthcare Conference

    Summit Therapeutics has announced that CFO Mr Erik Ostrowski will present at the 26th Annual Oppenheimer Healthcare Conference at 10:55am EST (3:55pm GMT) on Tuesday, 8 December 2015 in New York...

  • 02 Dec
    12:12
    Summit achieves first milestone in strategic alliance with Oxford Uni

    Summit Therapeutics has announced the achievement of the first research milestone as part of its multi-year strategic alliance with the University of Oxford. It says the collaboration is focussed...

  • 23 Nov
    12:18
    Summit announces success of clinical trial

    Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), has announced the success of CoDIFy,...

  • 18 Sep
    13:46
    Summit presents new data on CDI antibiotic

    Summit has announced new preclinical data on SMT19969, a novel and selective oral antibiotic for the treatment of C. difficile infection will be presented at the 55th Interscience Conference on...

  • 10 Sep
    12:22
    SUMM completes enrolment for SMT19969 P2 trial

    Summit Therapeutics has announced the completion of patient enrolment into the CoDIFy Phase 2 proof of concept trial of SMT19969 for the treatment of CDI. Patient dosing and follow-up is...

  • 04 Sep
    13:13
    Summit employees granted 120,000 options

    Summit Therapeutics has granted options over 120,000 ordinary shares to employees under the existing company share option plan. The options have an exercise price of 149 pence per share, the...

  • 27 Aug
    12:20
    Summit Therapeutics losses widen

    Summit Therapeutics has reported its financial results for the second quarter and half-year ended 31 July 2015 which show that the Company had generated a loss for the three months ended 31 July...

  • 24 Aug
    12:11
    Summit Therapeutics confirms 2Q results date

    Summit Therapeutics has confirmed that it will be reporting its second quarter financial results for the period ending 31 July 2015 on Thursday, 27 August 2015. The Company will also host a...

  • 07 Jul
    12:27
    Summit obtains European patent for DMD drug

    Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection, has announced that the European Patent Office...

  • 17 Jun
    13:40
    Summit Therapeutics options exercised

    Summit Therapeutics has issued 127,315 new ordinary shares following the exercise of employee share options. At 1:40pm: (LON:SUMM) Summit Therapeutics PLC share price was -2p at 141.5p Story...

  • 24 Mar
    14:57
    Summit Therapeutics options exercised

    Summit Therapeutics has issued 27,384 new ordinary shares following the exercise of options - 16,777 at 65p apiece and 10,607 at 20p each. At 2:57pm: (LON:SUMM) Summit Corporation PLC share...

  • 05 Mar
    07:09
    FLASH: SUMM announces pricing of US IPO

    Story provided by StockMarketWire.com

  • 23 Feb
    07:07
  • 20 Feb
    07:21
    SUMM's trial

    Summit Therapeutics said first patients with Duchenne Muscular Dystrophy (DMD) and C. difficile infection have been enrolled and dosed in a Phase 1b modified diet clinical trial of the orally...

  • 20 Feb
    07:06
    FLASH: SUMM doses first patients in CMTC1100 phase 1B trial

    Story provided by StockMarketWire.com

  • 03 Feb
    14:37
    Summit to host general meeting

    Summit, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, has announced that a circular and notice of a general meeting has...

  • 11 Dec
    07:26
  • 05 Dec
    12:04
    Summit to present at the Oppenheimer Healthcare Conference

    Summit Corporation, the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection ('CDI'), has announced that it will be...

  • 03 Dec
    07:17
    FLASH: Summit Corp director Jim Mellon resigns

    Story provided by StockMarketWire.com

  • 08 Oct
    07:49
    SUMM gives positive data on Utrophin modulation programme

    Summit Corp. reports clinical data on SMT C1100, its lead utrophin modulator, highlighting its safety profile and further detailing the observed reduction in enzymes associated with muscle damage...

Shares Magazine

Shares Magazine

Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.

Don't miss the latest news! Sign up today

Investor Events

Investor Events

Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.

Terms & Conditions | Privacy Policy | Cookies